Ex­tend­ed FTC re­view adds wrin­kle to Sanofi's $2.9B Proven­tion Bio buy­out

Sanofi is ex­tend­ing the dead­line for its $2.9 bil­lion ac­qui­si­tion of Proven­tion Bio to give an­titrust reg­u­la­tors more time to re­view the deal.

The French phar­ma gi­ant with­drew and re­filed the Pre­merg­er No­ti­fi­ca­tion and Re­port Form un­der the Hart-Scott-Rodi­no An­titrust Im­prove­ments Act “fol­low­ing in­for­mal dis­cus­sions with the staff of the” Fed­er­al Trade Com­mis­sion (FTC), it said in an SEC fil­ing. The agency, it added, need­ed more time to look at the deal and “in­for­ma­tion re­cent­ly pro­vid­ed to them.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER